tradingkey.logo

Bristol Myers Squibb Announces Topline Results From Phase 3 Independence Trial For Reblozyl® (Luspatercept-Aamt) In Adult Patients With Myelofibrosis-Associated Anemia

ReutersJul 18, 2025 12:27 PM

Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB ANNOUNCES TOPLINE RESULTS FROM PHASE 3 INDEPENDENCE TRIAL FOR REBLOZYL® (LUSPATERCEPT-AAMT) IN ADULT PATIENTS WITH MYELOFIBROSIS-ASSOCIATED ANEMIA

  • BRISTOL-MYERS SQUIBB CO - REBLOZYL DID NOT MEET PRIMARY ENDPOINT IN PHASE 3 TRIAL

  • BRISTOL-MYERS SQUIBB CO - SECONDARY MEASURES SHOWED BENEFITS FAVORING REBLOZYL

  • BRISTOL-MYERS SQUIBB CO - BRISTOL MYERS SQUIBB TO DISCUSS MARKETING APPLICATIONS WITH FDA AND EMA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI